[go: up one dir, main page]

AR028327A1 - Formas de presentacion transdermales o transmucosales que contienen una combinacion de principios activos destinada a la deshabituacion de fumadores - Google Patents

Formas de presentacion transdermales o transmucosales que contienen una combinacion de principios activos destinada a la deshabituacion de fumadores

Info

Publication number
AR028327A1
AR028327A1 ARP010101728A ARP010101728A AR028327A1 AR 028327 A1 AR028327 A1 AR 028327A1 AR P010101728 A ARP010101728 A AR P010101728A AR P010101728 A ARP010101728 A AR P010101728A AR 028327 A1 AR028327 A1 AR 028327A1
Authority
AR
Argentina
Prior art keywords
dishabitation
smokers
transmucosal
transdermal
combination
Prior art date
Application number
ARP010101728A
Other languages
English (en)
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of AR028327A1 publication Critical patent/AR028327A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP010101728A 2000-04-15 2001-04-11 Formas de presentacion transdermales o transmucosales que contienen una combinacion de principios activos destinada a la deshabituacion de fumadores AR028327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10018834A DE10018834A1 (de) 2000-04-15 2000-04-15 Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung

Publications (1)

Publication Number Publication Date
AR028327A1 true AR028327A1 (es) 2003-05-07

Family

ID=7638944

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101728A AR028327A1 (es) 2000-04-15 2001-04-11 Formas de presentacion transdermales o transmucosales que contienen una combinacion de principios activos destinada a la deshabituacion de fumadores

Country Status (21)

Country Link
US (1) US20030049308A1 (es)
EP (1) EP1274405B1 (es)
JP (1) JP2004501090A (es)
KR (1) KR100601901B1 (es)
CN (1) CN1423556A (es)
AR (1) AR028327A1 (es)
AT (1) ATE268168T1 (es)
AU (1) AU5624601A (es)
BR (1) BR0110060A (es)
CA (1) CA2404581A1 (es)
DE (2) DE10018834A1 (es)
DK (1) DK1274405T3 (es)
ES (1) ES2220772T3 (es)
HU (1) HUP0300048A3 (es)
IL (1) IL152152A0 (es)
MX (1) MXPA02009104A (es)
NZ (1) NZ521155A (es)
PL (1) PL358212A1 (es)
RU (1) RU2301671C2 (es)
WO (1) WO2001080837A2 (es)
ZA (1) ZA200206758B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10224612A1 (de) * 2002-06-04 2003-12-24 Lohmann Therapie Syst Lts Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung
AU2003268026A1 (en) * 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
DE10256775A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Filmförmige Zubereitungen zur transmucosalen Verabreichung von Nicotin, sowie Verfahren zu deren Herstellung
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
KR100858852B1 (ko) 2002-12-27 2008-09-17 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
US20050277626A1 (en) * 2004-05-27 2005-12-15 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102005010255A1 (de) 2005-03-07 2006-09-14 Lts Lohmann Therapie-Systeme Ag Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung
EP1993509A2 (en) 2006-02-17 2008-11-26 Novartis AG Disintegrable oral films
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
DE102006027795A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Raucherentwöhnungs-Kombinationswafer
US8956602B2 (en) * 2006-12-05 2015-02-17 Landec, Inc. Delivery of drugs
WO2008112124A2 (en) 2007-03-07 2008-09-18 Novartis Ag Orally administrable films
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.
WO2014105783A1 (en) * 2012-12-28 2014-07-03 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
WO2014145045A1 (en) * 2013-03-15 2014-09-18 Tonix Pharmaceuticals, Inc. Compositions and methods for transmucosal absorption
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12433904B2 (en) 2019-04-17 2025-10-07 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2265364B1 (es) * 1974-03-29 1977-11-04 Creat
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
US4385053A (en) * 1981-03-11 1983-05-24 Barry Reisberg Treatment for human memory impairment associated with aging
US5783207A (en) * 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
GB8612366D0 (en) * 1986-05-21 1986-06-25 Erba Farmitalia Ergoline esters
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5059600A (en) * 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5219858A (en) * 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE69420746T2 (de) * 1994-06-02 2000-06-29 Dan Riga Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung
AU2703795A (en) * 1994-06-23 1996-01-19 Procter & Gamble Company, The Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
DE19527925C2 (de) * 1995-07-29 1997-07-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht
CA2220768A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US6054492A (en) * 1996-09-09 2000-04-25 Supratek Pharma Inc. Fluorinated copolymeric pharmaceutical adjuncts
AU6250299A (en) * 1998-09-24 2000-04-10 Algos Pharmaceutical Corporation Method for reducing nicotine dependency
US6224897B1 (en) * 1998-09-29 2001-05-01 Novartis Consumer Health S.A. Methods to abate the use of tobacco by humans
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
PL195871B1 (pl) * 1998-12-18 2007-11-30 Alza Corp Urządzenie do przezskórnego dostarczania nikotyny
CN1239656A (zh) * 1999-02-10 1999-12-29 重庆医科大学 戒烟用复方烟碱与可乐定透皮贴剂
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
KR100601901B1 (ko) 2006-07-14
MXPA02009104A (es) 2003-03-12
CA2404581A1 (en) 2002-09-26
US20030049308A1 (en) 2003-03-13
DK1274405T3 (da) 2004-10-11
DE10018834A1 (de) 2001-10-25
CN1423556A (zh) 2003-06-11
HUP0300048A2 (hu) 2003-06-28
EP1274405A2 (de) 2003-01-15
DE50102481D1 (de) 2004-07-08
ZA200206758B (en) 2003-10-01
JP2004501090A (ja) 2004-01-15
KR20030025909A (ko) 2003-03-29
HUP0300048A3 (en) 2005-04-28
HK1051495A1 (en) 2003-08-08
NZ521155A (en) 2006-02-24
AU5624601A (en) 2001-11-07
WO2001080837A3 (de) 2002-02-21
BR0110060A (pt) 2003-07-15
ATE268168T1 (de) 2004-06-15
IL152152A0 (en) 2003-05-29
WO2001080837A2 (de) 2001-11-01
ES2220772T3 (es) 2004-12-16
EP1274405B1 (de) 2004-06-02
RU2002123887A (ru) 2004-03-10
RU2301671C2 (ru) 2007-06-27
PL358212A1 (en) 2004-08-09
AU2001256246B2 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
AR028327A1 (es) Formas de presentacion transdermales o transmucosales que contienen una combinacion de principios activos destinada a la deshabituacion de fumadores
NO20026037L (no) Sötvareprodukt som inneholder aktive bestanddeler
ATE311915T1 (de) Medikamentenspender
DE60142196D1 (de) Aerosolspender
ATE267570T1 (de) Verflüssigungshandstück
DE60116273D1 (de) Tabakverarbeitung
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DE60122224D1 (de) Zweiräumiger Verpackung
ATE540013T1 (de) Naphthalinderivate
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
ID29122A (id) Pembungkus popok sekali pakai
BR0100554B1 (pt) dispositivo de acondicionamento e de aplicação que possui uma estrutura porosa que incorpora um agente biocida.
DE50106776D1 (de) Anzeigeinstrument
EE200200701A (et) Kõrgkontsentreeritud stabiilsed meloksikaami lahused
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
AR028313A1 (es) Un procedimiento para la produccion de una composicion desodorante o antitranspirante
DE60109530D1 (de) Amorphe Mupirocin enthaltende Arzneimittel
DE60115599D1 (de) Steife zigarettenverpackung
DE50113956D1 (de) Anzeigeinstrument
DE50112350D1 (de) Arzneimittel enthaltend aktiviertes antithrombin iii
DE60123364D1 (de) Sterilisierungsmittelverdampfer
DE60100576D1 (de) Messuhr
ITBO20000684A0 (it) Pacchetto rigido per sigarette
EE200300045A (et) Kristalne ravimaine
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel

Legal Events

Date Code Title Description
FB Suspension of granting procedure